Jazz Pharma inks deal with Saniona to develop SAN2355

Ireland-headquartered Jazz Pharmaceuticals (Nasdaq JAZZ) and Denmark’s Saniona (Nasdaq OMX: SANION) have entered into a global license agreement for Jazz to obtain exclusive worldwide rights to develop SAN2355, a highly differentiated, subtype-selective Kv7.2/Kv7.3 activator.

Saniona’s shares leapt as much as 58% to 12.92 kroner on the news of the potentially over billion-dollar deal.

The compound is in pre-clinical development for epilepsy and other potential indications, designed to overcome the limitations of non-selective Kv7-targeting compounds. Jazz will lead and fund further development, regulatory submissions, and global commercialization activities.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week.

Related Posts

ICMR-NIN study links micronutrient deficiencies to higher dementia risk

Hyderabad – A groundbreaking study by the Indian Council of Medical Research’s National Institute of Nutrition (ICMR-NIN) has established a clear association between micronutrient deficiencies and elevated dementia risk among Indian…

Pvt nursing home sealed in Chatra after woman, unborn baby die

Chatra: The Chatra administration on Sunday sealed a private nursing home operating near Chatra bus stand following the death of a 20-year-old pregnant woman and her unborn child. The deceased…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

ICMR-NIN study links micronutrient deficiencies to higher dementia risk

ICMR-NIN study links micronutrient deficiencies to higher dementia risk

Pvt nursing home sealed in Chatra after woman, unborn baby die

Pvt nursing home sealed in Chatra after woman, unborn baby die

30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

30 docs from 9 states guilty of taking pharma company junket, no action yet by 6 state medical councils

Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy

Scheme to build bulk drugs’ R&D, capacity in works, says Pharma secy

Drug companies directed to step up vigil on adverse reactions

Drug companies directed to step up vigil on adverse reactions

Maharashtra FDA seizes medical devices, gloves worth ₹2.17 cr in crackdown on irregularities

Maharashtra FDA seizes medical devices, gloves worth ₹2.17 cr in crackdown on irregularities